This episode breaks down a pivotal week in GLP-1 obesity medicine, from early trial headlines that overstated results to the launch of the first FDA-approved Wegovy pill for obesity. We also examine manufacturing quality concerns, patient trust, and why accountability matters as access to these medications rapidly expands.**